Tag Archives: diabetes

  • End of Winter Miscellany

    [ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]

  • “Triple-Digit Profits from the Diabetic ‘Patch’ Company Going to $1 Billion.”

    Today the pitch that’s been catching my eye is from Mitchell Clark for his Biotech Breakthrough Stock Report — we haven’t covered this newsletter before, but we have certainly covered teaser spiels from Mitchell Clark’s wide variety of Lombardi-published newsletters in the past (before he was a biotech expert this week, he was a bible […]

  • The Why and the What of Diabetes Management

    [ed. note: Michael Jorrin, a longtime medical writer who we like to call “Doc Gumshoe” (he’s not a doctor), shares his thoughts and explanations of health and medical topics with Gumshoe readers every few weeks. Readers have asked him about diabetes, both for personal reasons and because of the huge investment opportunity, so he submitted […]

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.